Results from the Phase I trial in rosacea showed that EP0003 was well tolerated and that the pharmacokinetics properties were as predicted. No clinical improvements were seen, often the case in short Phase I studies.
Since several recent reports (*) describe beneficial effects with tranexamic acid in melasma, oral treatment better than topical, this indication is our current focus. EP0003 being much more potent and lipophilic than tranexamic acid offer opportunities for improved topical treatment, avoiding potential effects on blood coagulation associated with oral use of tranexamic acid.
We are now looking for a partner to perform clinical studies in melasma.
* E.g. “Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review”, Hyun Jung KIM et.al. Acta Derm Venereol 2017; 97: 776–781
Copyright © All Rights Reserved